Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new stand...

Full description

Bibliographic Details
Main Authors: Mariona Riudavets, MD, PhD, Arshid Azarine, MD, MSc, Sondes Smaali, MD, Young-Wouk Kim, MD, Vincent Thomas de Montpréville, MD, Alina Miruna Grecea, MD, Charles Naltet, MD, Annas Gazzah, MD, David Planchard, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
HER2 mutation
Antibody drug conjugates
Trastuzumab deruxtecan
Cardiotoxicity: Case Report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001564

Similar Items

Similar Items